A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Azilsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 15 Feb 2017 Planned End Date changed from 1 Jun 2019 to 30 Jun 2019.
- 06 Jul 2016 Status changed from not yet recruiting to recruiting.
- 09 Jun 2016 New trial record